Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Prospective Randomised, Open-labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
Brief Summary: The purpose of this study is to determine the safety and efficacy of sirolimus-based immunosuppressive therapy in patients following orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), with regard to HCC recurrence-free patient survival.


Options:
A: Inclusion Criteria:

* Age \> 18 years
* Recipient of a primary liver graft
* Absence of any of our exclusion criteria

Exclusion Criteria:

* Pretransplant renal failure, defined as serum creatinine \> 1.5 mg/dL
* Severe pretransplant thrombopenia, defined as platelets \< 50000/mL
* Combined liver-kidney transplantation
* Autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis as causes of liver transplantation
* Chronic hepatic encephalopathy
* Living donor liver transplantation
* Recipient with human immunodeficiency virus infection
* Severe pretransplant leukopenia, defined as \< 1500 leukocytes/mL
B: Inclusion Criteria:

1. Age 18 years and older
2. Histologically proven HCC before randomisation
3. Signed, written informed consent

Exclusion Criteria:

1. Multiple-organ recipients.
2. Known hypersensitivity to sirolimus or its derivatives.
3. Hyperlipidemia refractory to optimal medical management. (cholesterol \>300 mg/dL; triglycerides \>350 mg/dL).\*
4. Evidence of significant local or systemic infection.
5. Known HIV-positive patients.\*
6. Platelets \<75,000/cubic mm.\*
7. Women of child-bearing potential not willing to take contraception.
8. Patients with non-HCC malignancies within the past 5 years,excluding successfully treated squamous cell carcinoma and basal cell carcinoma of the skin.
9. Extrahepatic HCC tumor manifestation
10. Patients with a psychologic, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.
11. Patients under guardianship (e.g. individuals who are not able to freely give their informed consent).
C: Inclusion Criteria:

* Recipient of living donor liver transplantation for HCV-related cirrhosis

Exclusion Criteria:

* ABO blood type incompatible transplant case
* Renal dysfunction (serum creatinine \>2.0 mg/dL)
* WBC \< 1,000/mm3
* Hemoglobin \< 8 g/dL
* Platelet \<30,000 /mm3
D: Inclusion criteria:

Male or female recipients of a full-size liver allograft, aged 18 to 65 years.

Exclusion criteria:

Patients with thrombocytopenia (platelets \<50,000/mm³), with an absolute neutrophil count of \<1,000/mm³ or leucopenia (leucocytes \<2000/mm³), with anemia with Hb \< 6g/dl at time of randomization

Patients with uncontrolled hypercholesterolemia (\>350mg/dL; \>9mmol/L) or hypertriglyceridemia (\>750 mg/dL; \>8.5 mmol/L) at time of randomization

History of malignancy of any organ system within the past 5 years whether or not there is evidence of local recurrence or metastases, other than non-metastatic basal or squamous cell carcinoma of the skin or HCC

Answer: B